(Reuters) - Aptamers are chemically synthesised nucleic acids, which are
much less expensive to produce than monocolonal antibodies.
"Aptamers have the potential to play a key role in the next
generation of drugs in our core therapeutic areas," said
Bernhard Kirschbaum, a director of research at Merck Serono.
Read more at Reuters.com Mergers News
much less expensive to produce than monocolonal antibodies.
"Aptamers have the potential to play a key role in the next
generation of drugs in our core therapeutic areas," said
Bernhard Kirschbaum, a director of research at Merck Serono.
Read more at Reuters.com Mergers News
No comments:
Post a Comment